Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Integra LifeSciences Q1 2026 Earnings Call - CEO Returns, Revenue Beats, and Tariff Tailwinds
Integra LifeSciences delivered a strong first quarter, beating revenue and EPS guidance as returning supply and favorable tariff refunds lifted results. The company is raising its full-year adjusted E...
- CEO Transition: Stuart Essig has returned as CEO and Chairman, replacing Mojdeh Poul. He emphasized a renewed focus on commercial execution, customer alignment, and organizational culture, while affirming that existing transformation and compliance initiatives remain unchanged.
- Strong Q1 Results: Total revenue reached $392 million, up 2.4% reported and 1.3% organic. Adjusted EPS came in at $0.54, beating the high end of guidance by approximately $0.10, driven by revenue growth, favorable product mix, and tariff benefits.
- Guidance Update: The company is maintaining its 2026 revenue guidance of $1.66 billion-$1.70 billion but is raising full-year adjusted EPS guidance to $2.40-$2.50, up $0.10, reflecting a $0.02 per share benefit from IEEPA tariff refunds and improved operational performance.
- +7 more takeaways
TransMedics Q1 2026 Earnings Call - Aggressive Growth Investments and CHOPS Pivot Expand Addressable Market
TransMedics delivered a strong Q1 2026, with revenue growing 21% year-over-year to $174 million and adjusted operating profit of $18.1 million. The company is executing a deliberate, capital-intensive...
- Total revenue reached $174 million in Q1 2026, up 21% year-over-year and 8% sequentially, driven by strong liver performance and growing logistics services.
- U.S. transplant product revenue grew 22% year-over-year to $102 million, while international revenue surged 39% to $6 million, signaling early but meaningful global traction.
- Adjusted operating profit came in at $18.1 million, representing a 10.4% adjusted operating margin, with management citing near-term margin pressure due to strategic investments.
- +7 more takeaways
Latham Group Q1 2026 Earnings Call - Sand State Strategy Drives Fiberglass Growth Amid Macro Headwinds
Latham Group delivered a resilient start to 2026, posting 5% net sales growth to $117 million despite adverse weather and a flat U.S. pool start outlook. The quarter was defined by double-digit sales ...
- Net sales rose 5% year-over-year to $117 million, driven by 3% organic growth and a one-month contribution from the Freedom Pools acquisition.
- Gross margins expanded 220 basis points to 32%, fueled by volume leverage and ongoing lean manufacturing and value engineering initiatives.
- SG&A expenses jumped 20% to $37 million, reflecting strategic investments in sales, marketing, digital transformation, and $2.3 million in Coverstar Central earn-out costs.
- +7 more takeaways
"Veeco Q1 2026 Earnings Call - $250M Indium Phosphide Order Signals AI Optical Infrastructure Inflection
Veeco delivered a solid Q1 2026, with revenue of $158 million and non-GAAP EPS of $0.14, landing within guidance despite a modest gross margin dip to 36% from a single China-related LSA shipment delay...
- Q1 2026 revenue came in at $158 million, with non-GAAP diluted EPS of $0.14, both within management’s guidance range.
- Gross margin landed at 36%, slightly below the 37.7% prior quarter, largely due to a single $8 million LSA system shipment delay to a Chinese customer following new BIS licensing requirements.
- Veeco secured over $250 million in new orders for indium phosphide laser manufacturing equipment, driven by the industry transition from copper to optical interconnects in AI data centers.
- +10 more takeaways
FIGS Q1 2026 Earnings Call - Revenue Surges 28% as Active Customers Top 3 Million and Profitability Widens
FIGS delivered a powerhouse start to fiscal 2026, with net revenue jumping 28% year-over-year to $159.9 million and beating top-line expectations. The company crossed the 3 million active customer mil...
- Net revenue grew 28% year-over-year to $159.9 million, beating the low 20% growth guide.
- Active customers surpassed 3 million for the first time, with acquisition accelerating to 12% year-over-year.
- Adjusted EBITDA margin reached 8.7%, exceeding guidance by 170 basis points and up from 7.3% last year.
- +7 more takeaways
RadNet Inc Q1 2026 Earnings Call - Advanced Imaging Shift and Digital Health Acceleration Drive Record Revenue
RadNet delivered record first-quarter 2026 revenue and adjusted EBITDA, driven by a decisive industry shift toward advanced imaging and accelerating Digital Health integration. Despite an estimated $1...
- Record Q1 2026 Performance: Revenue grew 22.1% and adjusted EBITDA increased 36.3% year-over-year, setting new quarterly records despite an estimated $13 million revenue impact from severe East Coast weather.
- Margin Expansion: Reported adjusted EBITDA margins improved by 115 basis points. On a normalized basis, excluding weather and prior-year wildfire impacts, margins expanded by 52 basis points, reflecting operational efficiency.
- Advanced Imaging Dominance: Advanced imaging now represents 29.3% of procedural volume, up 235 basis points year-over-year. This segment drives over 60% of revenue despite being a smaller volume share, highlighting superior profitability.
- +7 more takeaways
Neurocrine Biosciences Q1 2026 Earnings Call - Record Sales Drive Pipeline Expansion and Soleno Acquisition
Neurocrine Biosciences delivered a record-breaking first quarter, with net product sales surpassing $800 million for the first time in company history. This 44% year-over-year growth was anchored by I...
- Neurocrine Biosciences reported record first-quarter 2026 net product sales exceeding $800 million, marking a 44% year-over-year growth and the highest quarterly sales in the company’s history.
- INGREZZA sales reached $657 million, up 20% year-over-year, driven by double-digit volume growth and record new patient additions, reaffirming 2026 guidance of $2.7 billion to $2.8 billion.
- CRENESSITY sales hit $153 million in Q1 2026, with the asset now annualizing at over $600 million per year, supported by strong patient persistency, broad prescriber adoption, and favorable reimbursement dynamics.
- +7 more takeaways
The Mosaic Company Q1 2026 Earnings Call - Sulfur Shortage Forces Production Curtailments
The Mosaic Company navigated a volatile Q1 2026 defined by geopolitical shocks in the Middle East, which slashed global sulfur supplies and compressed phosphate stripping margins to unsustainable leve...
- Geopolitical conflict in the Persian Gulf has disrupted roughly 20% of global phosphate and half of seaborne sulfur volumes, creating an unprecedented supply squeeze that is driving raw material costs to unsustainable levels for fertilizer producers.
- Mosaic sold 1.9 million tons of phosphate in Q1 2026, marking its highest quarterly sales volume in five years, driven by deferred demand and the company’s ability to pivot product to international markets with stronger pricing.
- U.S. phosphate facilities are operating near targeted rates, with three of four plants running at or above 80% utilization following a major turnaround at the New Wales facility, showcasing improved asset reliability.
- +7 more takeaways
Agibank Q1 2026 Earnings Call - Resilient Growth Amid Regulatory Shifts and Hybrid Model Execution
Agibank delivered a solid first quarter in 2026, with active customers growing 53% year-over-year to over 7 million and total loans rising 30% to BRL 35.5 billion. The bank’s hybrid model, blending se...
- Active customers grew 53% year-over-year to over 7 million, with mature customers averaging more than seven products, highlighting strong cross-sell potential.
- Total loan balances rose 30% year-over-year to BRL 35.5 billion, with secured loans at 87% and unsecured loans at 13% of the portfolio.
- Revenue reached BRL 3 billion, up 24% year-over-year, driven by net interest income growth of 9% and fee revenue recovery.
- +7 more takeaways
Jacobs {Q2} {2026} Earnings Call - AI Infrastructure and PA Consulting Drive Record Backlog and Raised Outlook
Jacobs delivered a second consecutive quarter of raised guidance, driven by 9% organic net revenue growth and a 22% year-over-year jump in adjusted EPS to $1.75. The company’s backlog hit a new record...
- Adjusted EPS grew 22% to $1.75, driven by 9% organic net revenue growth and 70 basis points of margin expansion.
- Record backlog of $27 billion, with a 1.4x trailing book-to-bill ratio on gross revenue and 1.2x on net revenue.
- Data center revenue more than doubled year-over-year, reflecting surging demand from hyperscalers and AI infrastructure build-out.
- +9 more takeaways